Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,971 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,884 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05920798 | Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer(FRAPPE) | active not recruiting | Phase 1 / Phase 2 | 38 | Mayo ClinicOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05983432 | Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors | recruiting | Phase 1 | 540 | SystImmune Inc.INDUSTRY | 5 | Sep 21, 2026 |
| clinicaltrials |
| NCT06005740 | A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer | active not recruiting | Phase 1 | 70 | TORL Biotherapeutics, LLCINDUSTRY | 2 | Sep 21, 2026 | clinicaltrials |
| NCT06021626 | A Study of CRD3874-SI in People With Solid Tumors | recruiting | Phase 1 | 81 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06029309 | Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma(ZANU-TAFA) | recruiting | Phase 1 / Phase 2 | 27 | Alvaro Alencar, MDOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06114511 | A Study of BL-M07D1 in Patients With HER2-Overexpressing or HER2-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 78 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06169579 | An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers | enrolling by invitation | Phase 1 | 96 | Shenzhen NewDEL Biotech, Co., LtdINDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06260514 | Study of APR-1051 in Patients With Advanced Solid Tumors(ACESOT-1051) | recruiting | Phase 1 | 90 | Aprea TherapeuticsINDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06349590 | Manipulation of the Gut Microbiome by a Standardized Preoperative Diet to Prevent Colorectal Cancer Recurrence and Metastasis Following Surgery(DIET) | recruiting | Phase 1 / Phase 2 | 80 | University of ChicagoOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06439836 | Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy | recruiting | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06529822 | Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease | recruiting | Phase 1 | 64 | Washington University School of MedicineOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06717750 | A Study of CSCJC3456 in Patients With Advanced Malignant Tumors | recruiting | Phase 1 | 102 | Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06736379 | Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer | recruiting | Phase 1 | 41 | VLP TherapeuticsINDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07162038 | Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation | recruiting | Phase 1 | 155 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07524855 | A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer(HLD-0117) | recruiting | Phase 1 | 170 | Janssen Research & Development, LLCINDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07562841 | Au-TMP and Radiotherapy for Advanced Melanoma With Anti-PD-1 Therapy | recruiting | Phase 1 | 6 | West China HospitalOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07629960 | A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations | recruiting | Phase 1 / Phase 2 | 265 | Blueprint Medicines CorporationINDUSTRY | 2 | Sep 21, 2026 | clinicaltrials |
| NCT07645651 | Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer | recruiting | Phase 1 | 15 | University of WashingtonOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07692529 | A Clinical Study on the Efficacy and Safety of Zeprumetostat in Relapsed/Refractory Large Granular Lymphocyte Leukemia | not yet recruiting | Phase 1 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Sep 21, 2026 | clinicaltrials |
| NCT07693751 | A Study to Assess Safety and Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 100 | SOTIO Biotech a.s.INDUSTRY | 2 | Sep 21, 2026 | clinicaltrials |
| NCT07802717 | A Phase 1 Dose-escalation and Expansion Study of In Vivo BCMA-CAR T Cell Therapy (VV169) in Patients With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 40 | Vyriad, Inc.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07830199 | A Clinical Study of SHR-4595 Injection in Patients With Advanced Solid Tumors to Evaluate Safety, Tolerability and Pharmacokinetics | not yet recruiting | Phase 1 | 208 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07831122 | Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE) | not yet recruiting | Phase 1 | 108 | Canadian Myeloma Research GroupOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07831187 | Entacapone Plus Bevacizumab for Glioblastoma at First Recurrence | not yet recruiting | Phase 1 / Phase 2 | 96 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07832266 | Proactively Intervening On Early Cranial Nerve Injury As A Delayed Sequela Of Oropharyngeal Cancer: A Randomized Feasibility Clinical Trial For Pro-Habilitation (proNERVE RCT) | not yet recruiting | Phase 1 | 48 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT00515372 | Depression Treatment and Screening in Ovarian Cancer Patients | active not recruiting | Phase 1 | 409 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT01872260 | Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 259 | Novartis PharmaceuticalsINDUSTRY | 8 | Sep 18, 2026 | clinicaltrials |
| NCT02530034 | Hu8F4 in Treating Patients With Advanced Hematologic Malignancies | active not recruiting | Phase 1 | 72 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT03214562 | Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 116 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT03508752 | Neurocognitive Decline in Patients With Brain Metastases | active not recruiting | Phase 1 / Phase 2 | 80 | University of Texas Southwestern Medical CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT03587038 | OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma | active not recruiting | Phase 1 | 27 | University of OklahomaOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT03630991 | Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy | recruiting | Phase 1 | 58 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04038619 | Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients | recruiting | Phase 1 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04234568 | Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors | active not recruiting | Phase 1 | 31 | National Cancer Institute (NCI)NIH | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04248582 | Cryotherapy for Locally Advanced Esophageal Cancer | active not recruiting | Phase 1 | 14 | Hunter Holmes Mcguire Veteran Affairs Medical CenterFED | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04693468 | Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial | recruiting | Phase 1 | 111 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04734990 | Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | active not recruiting | Phase 1 / Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04752826 | BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20) | recruiting | Phase 1 / Phase 2 | 250 | BioInvent International ABINDUSTRY | 7 | Sep 18, 2026 | clinicaltrials |
| NCT05025800 | ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05141513 | Intraoperative Radiation Therapy After Stereotactic Body Radiation Therapy and Chemotherapy in Treatment of Pancreatic Adenocarcinoma | active not recruiting | Phase 1 | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05267626 | Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer | recruiting | Phase 1 / Phase 2 | 159 | Aulos Bioscience, Inc.INDUSTRY | 2 | Sep 18, 2026 | clinicaltrials |
| NCT05327023 | Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies | recruiting | Phase 1 / Phase 2 | 430 | National Cancer Institute (NCI)NIH | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05627245 | Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment | active not recruiting | Phase 1 | 48 | National Cancer Institute (NCI)NIH | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06085729 | Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC) | recruiting | Phase 1 / Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06088472 | TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors | active not recruiting | Phase 1 | 12 | Grit BiotechnologyINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06284486 | A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib | recruiting | Phase 1 / Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06398418 | R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors | recruiting | Phase 1 | 33 | Rise Therapeutics LLCINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06563375 | Phase 1 Dose Escalation and Dose Expansion Trial of NP-101 in Patients With Solid Tumors | recruiting | Phase 1 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06746688 | A First-in-human, Clinical Trial Assessing the Safety of ES2B-C001-S01 With or Without [Adjuvant] in Patients With HER2-expressing Metastatic Breast Cancer. | active not recruiting | Phase 1 | 40 | ExpreS2ion BiotechnologiesINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06769490 | Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia | recruiting | Phase 1 | 44 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
Data updated 5 days agoSource updated Sep 21, 2026source: clinicaltrials